Scientific Board of Advisors
Dr. Robert Mach, PhD
Dr. Mach is the Co-Founder of Trevarx and Inventor of [¹⁸F]FTT and [²¹¹At]PTT. He is the Britton Chance Professor of Radiology and Director of the PET Radiochemistry Program at the University of Pennsylvania. Dr. Mach is a past President of the Radiopharmaceutical Sciences Council of the Society of Nuclear Medicine & Molecular Imaging and a former member of the Board of Directors of the Society of Radiopharmaceutical Sciences. Research in his lab is focused on development of radiotracers for studying the molecular basis of disease using the imaging technique, positron emission tomography or PET. He holds 27 patents on the development of PET-based radiopharmaceuticals.
Dr. David Mankoff, MD/PhD
Dr. Mankoff is Co-Founder of Trevarx and the Matthew J. Wilson Professor and Vice Chair for Research in the Department of Radiology and the Associate Director of Education and Training for the Abramson Cancer Center at the University of Pennsylvania. He is a past member and president of the American Board of Nuclear Medicine and a fellow of the Society of Nuclear Medicine & Molecular Imaging. Dr. Mankoff is an experienced leader of multi-center trials as the past Chair of ECOG-ACRIN Cancer Research Group’s Experimental Imaging Science Committee, as well as an expert in translational cancer science as the current Co-Chair of the ECOG-ACRIN Scientific Planning Committee.
Dr. Farrokh Dehdashti, MD
Farrokh Dedashti is Professor of Radiology, Senior Vice Chair and Director Division of Nuclear Medicine, Mallinckrodt Institute of Radiology, Washington University in St. Louis. She is the PET Medical Director of the Center for Clinical Imaging Research (CCIR), a center for PET and PET/CT research imaging and Co-Leader of Oncologic Imaging Program of the Siteman Cancer Center. Her research has focused in translational oncologic studies with emphasis on receptor imaging and she has designed and executed the first human use of a variety of novel radiotracers developed at Washington University such as 16β-[¹⁸F]]fluoro-5α-dihydrotestosterone (FDHT) and Cu-diacetyl-bis (N4-methylthiosemicarbazone) (Cu-ATSM) and holds hold Investigational New Drug (IND) applications for several radiotracers, including F-18-FluorThanatrace ([¹⁸F]FTT), a PARP imaging agent.